Panelists discuss current frontline therapeutic strategies for advanced melanoma, highlighting the rationale and evolution of combination immunotherapy approaches.
Rapidly Evolving Frontline Paradigm in Metastatic Melanoma
Panelists discuss long-term efficacy and safety outcomes from pivotal studies evaluating dual immune checkpoint inhibition in advanced melanoma.
Panelists analyze results from an indirect treatment comparison evaluating different combination immunotherapies in advanced melanoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
2
FDA Approves Novel Interchangeable Biosimilar for Pertuzumab in HER2+ Breast Cancer
3
Rethinking Advanced Prostate Cancer: Surprising Finds from a Landmark Study
4
Reviewing Long-Term CLL Treatment With BTK Inhibitor Zanubrutinib
5
